Products & Services · Research and development funding expense
Phase 2b, TEV-408 — Research and development funding expense
Analysis
StatementSegment
CategoryEfficiency
SignalLower is better
VolatilityVolatile
First reportedQ1 2026
Last reportedQ1 2026
Rolls up toR&D
How to read this metric
Higher expenses typically reflect accelerated clinical trial activity or increased operational costs, whereas lower expenses may indicate trial delays, cost-saving measures, or the winding down of specific development phases.
Detailed definition
This metric tracks the actual cash outflow or recognized accounting expense incurred during a specific period for the re...
Peer comparison
Comparable to periodic R&D expenditure reporting for specific clinical programs at other pharmaceutical companies or life science investment firms.
Metric ID:
rprx_segment_phase_2b_tev_408_research_and_development_funding_expenseHistorical Data
1 periods
| Q1 '26 | |
|---|---|
| Value | $14.30M |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Royalty Pharma's phase 2b, tev-408 — research and development funding expense?
- Royalty Pharma (RPRX) reported phase 2b, tev-408 — research and development funding expense of $14.30M in Q1 2026.
- What does phase 2b, tev-408 — research and development funding expense mean?
- The actual costs incurred during the reporting period to fund the Phase 2b clinical trial activities for the TEV-408 drug candidate.